🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsTirzepatide (Mounjaro / Zepbound)Compounded tirzepatide — current market analysis Page 5

Compounded tirzepatide — current market analysis

KevinCompounds Thu, Jun 4, 2026 at 8:29 AM 23 replies 432 viewsPage 5 of 5
pam_stl
Member
267
1,123
Oct 2024
St. Louis, MO
Jun 6, 2026 at 6:37 AM#21
Dr.DermMIA said:
Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces…

This is my experience too, for whatever a second data point is worth. Posting only so the count is not one.

Last edited: Jun 6, 2026 at 11:37 AM
49 24Dr.ObesityMed, HealthEcon_DC, PedsEndoPhilly and 46 others
Reply Quote Save Share Report
emily_PDX
Member
245
1,123
Nov 2024
Portland, OR
Jun 6, 2026 at 8:43 PM#22
Dr.DermMIA said:
Worth adding the genuine exception, because it is real and narrow: a change made for an identified patient where the prescriber determines it produces…

Coming at Dr.DermMIA’s question from a different direction. They are two different exemptions from the same federal requirements and they buy different things. A 503A pharmacy is regulated primarily by the state board, needs a patient-specific prescription, is exempt from CGMP, and may use a bulk substance that has a USP monograph, is a component of an approved drug, or appears on the 503A bulks list — three independent doorways. A 503B outsourcing facility registers with the FDA, is inspected on a risk basis, must comply with CGMP, may compound for office stock without a patient-specific prescription, and has one doorway to a permitted bulk substance: the 503B bulks list, or the drug shortage list.

48 23PharmD_Rodriguez, julia.endo, JessicaM_2024 and 45 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jun 7, 2026 at 10:50 AM#23

Adding the numbers, since they settle part of this. For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine. Half the figures circulating in this community trace back to a secondary summary that dropped a qualifier.

Last edited: Jun 7, 2026 at 1:50 PM
47 22SkepticalSean, Dr.CardioMD, EndoResFellow and 44 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.PulmRoch
Member
456
2,345
Jun 2024
Rochester, MN
Jun 8, 2026 at 12:57 AM#24

Following on from Dr.DermMIA — and this may be the naive question:

Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?

Last edited: Jun 8, 2026 at 1:57 AM
46 21DebRD_ATL, KristenIndy, MarkLI_maint and 43 others
Reply Quote Save Share Report
JennaRN
Senior Member
1,987
8,923
Mar 2024
Colorado
Online
Jun 8, 2026 at 3:05 PM#25
dan_philly said:
For anyone reading later: the numbers in this thread are worth checking against a primary source before you act on them, including mine.

Careful with the causal language. Two things moving together in a period when five things changed is not a mechanism, and stating it as one makes the thread less useful to somebody reading it later.

Worth separating that from compounded supply, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

Last edited: Jun 8, 2026 at 4:05 PM
45 20SleepDoc_PDX, RegAffairsDC, BiostatsBrad and 42 others
Reply Quote Save Share Report
1345

Similar Threads

SURMOUNT-5: Tirzepatide vs semaglutide head-to-head — full results11 replies
SURPASS 1-5 program: tirzepatide T2DM efficacy data compilation6 replies
Tirzepatide dual agonism: GIP + GLP-1 synergistic mechanism18 replies
5mg → 10mg → 15mg titration — clinical guidance and real-world data8 replies
Zepbound insurance coverage — payer-by-payer breakdown 20268 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register